TAIPEI, Taiwan--(BUSINESS WIRE)--PharmaEngine, Inc. (TWO:4162) announced today that the British Journal of Cancer has published the paper “A Multinational Phase 2 Study of Nanoliposomal Irinotecan Sucrosofate (PEP02, MM-398) for Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer” (2013: 109 (4): 920-925) this August, and the Annals of Oncology has published the paper “A randomized phase II study of PEP02 (MM-398), irinotecan or docetaxel as a second-line therapy in patients with locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma“ (2013: 24 (6): 1567-1573) this June. The key results of these two studies were presented at the ASCO 2011 Gastrointestinal Cancers Symposium and ASCO 2011 Annual Meeting.
Help employers find you! Check out all the jobs and post your resume.
